Dyne Therapeutics Statistics
Total Valuation
DYN has a market cap or net worth of $2.44 billion. The enterprise value is $1.74 billion.
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DYN has 101.77 million shares outstanding. The number of shares has increased by 45.97% in one year.
| Current Share Class | 101.77M |
| Shares Outstanding | 101.77M |
| Shares Change (YoY) | +45.97% |
| Shares Change (QoQ) | +9.05% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 83.95% |
| Float | 74.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.46 |
| P/TBV Ratio | 3.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.02, with a Debt / Equity ratio of 0.04.
| Current Ratio | 17.02 |
| Quick Ratio | 16.73 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -68.69% and return on invested capital (ROIC) is -43.16%.
| Return on Equity (ROE) | -68.69% |
| Return on Assets (ROA) | -40.35% |
| Return on Capital (ROIC) | -43.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.09M |
| Employee Count | 141 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +90.25% in the last 52 weeks. The beta is 1.09, so DYN's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +90.25% |
| 50-Day Moving Average | 29.68 |
| 200-Day Moving Average | 32.68 |
| Relative Strength Index (RSI) | 32.86 |
| Average Volume (20 Days) | 891,372 |
Short Selling Information
The latest short interest is 10.35 million, so 10.17% of the outstanding shares have been sold short.
| Short Interest | 10.35M |
| Short Previous Month | 10.15M |
| Short % of Shares Out | 10.17% |
| Short % of Float | 13.85% |
| Short Ratio (days to cover) | 9.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -314.47M |
| Pretax Income | -257.40M |
| Net Income | -294.51M |
| EBITDA | -312.84M |
| EBIT | -314.47M |
| Earnings Per Share (EPS) | -$3.51 |
Full Income StatementBalance Sheet
The company has $723.67 million in cash and $24.86 million in debt, giving a net cash position of $698.82 million or $6.87 per share.
| Cash & Cash Equivalents | 723.67M |
| Total Debt | 24.86M |
| Net Cash | 698.82M |
| Net Cash Per Share | $6.87 |
| Equity (Book Value) | 705.54M |
| Book Value Per Share | 6.93 |
| Working Capital | 693.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$243.04 million and capital expenditures -$1.38 million, giving a free cash flow of -$244.42 million.
| Operating Cash Flow | -243.04M |
| Capital Expenditures | -1.38M |
| Free Cash Flow | -244.42M |
| FCF Per Share | -$2.40 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |